Core Viewpoint - The Hong Kong stock market saw a significant rise in brain-computer interface concept stocks, driven by Elon Musk's announcement that his company Neuralink plans to begin large-scale production of brain-computer interface devices in 2026 [1]. Group 1: Stock Performance - Nanjing Panda Electronics Co., Ltd. experienced a surge of over 14%, reaching a latest price of 5.540 with a total market capitalization of 50.63 billion [2]. - Heartway Medical-B saw an increase of 9.80%, with a latest price of 59.950 and a market cap of 22.89 billion [2]. - MicroPort Scientific Corporation rose by 7.43%, with a latest price of 12.140 and a market capitalization of 69.92 billion [2]. - BrainCo Inc. (Brain动极光-B) increased by 3.53%, reaching a price of 7.040 and a total market value of 89.15 billion [2]. - Lenovo Group Limited also saw a rise of 3.35%, with a latest price of 9.870 and a market capitalization of 1,224.347 billion [2].

Group 1 - Baidu Group-SW (09888) proposes to spin off Kunlun Chip for independent listing on the Hong Kong Stock Exchange main board [1] - Dali Group Holdings (01921) subsidiary Dali International Industrial Company has obtained a temporary industrial license issued by MIMR [1] - Guofu Hydrogen Energy (02582) has completed the delivery of a total of 424 sets of vehicle-mounted high-pressure hydrogen supply systems to its customers [1] Group 2 - CSPC Pharmaceutical Group (01093) has received clinical trial approval in China for its inhalation powder of Nintedanib [1] - Fantasia Holdings (01777) has entered into a restructuring agreement with Splendid Fortune to sell 409 million shares of Color Life for USD 4.5284 million [1] - China Hongqiao (01378) has made Hongtuo Industrial a wholly-owned subsidiary of Hongchuang Holdings [1] Group 3 - Brainstorm Cell Therapeutics-B (06681) subsidiary has officially signed a cooperation agreement with Beijing Jianguo Medical for a cognitive digital therapy project [1] - Longpan Technology (02465) plans to invest in a lithium iron phosphate production base with an annual capacity of 240,000 tons, with a total investment not exceeding 2 billion yuan [1] - Zhongzheng International (00943) intends to acquire a digital solution company in the beauty industry for HKD 62.5 million, with resumption of trading on January 5 [1] - Kelun-Biotech (06990) has received approval from the National Medical Products Administration for the clinical trial application of its ITGB6 ADC SKB105 new drug [1]

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to advance cognitive digital therapy, focusing on the assessment and training of cognitive functions from January 1, 2026, to December 30, 2026 [1] Group 1 - The collaboration aims to deepen technological exploration and productization in the mental health field, integrating cutting-edge AI algorithms with clinical needs to create more precise and universal digital therapy products [1] - The partnership will contribute to the establishment of industry standards and market normalization, enhancing the company's solution credibility and facilitating nationwide product promotion [2] - The project focuses on enhancing service capabilities in mental health welfare institutions and community settings, significantly expanding the coverage of the company's products and services while creating social benefits and new market growth opportunities [2] Group 2 - The collaboration with Beijing Jianguo Medical strengthens the company's network with national research institutions, accumulating real-world data that will drive algorithm iteration, product optimization, and innovative research and development [2]

Core Viewpoint - The company has signed a cooperation agreement with Beijing Jianguo Medical Technology Co., Ltd. to develop and promote cognitive digital therapy, aiming for standardization and accessibility in the field of cognitive disorders [1][2]. Group 1: Deepening Technical Exploration - The collaboration will enhance technical exploration and productization in mental health by integrating cutting-edge AI algorithms with clinical needs, leading to more precise and universal technology products [1]. Group 2: Establishing Industry Standards - The project will contribute to the establishment of national standards and market normalization, accumulating high-level evidence-based medical data and enhancing the authority of the company's solutions for nationwide promotion [2]. Group 3: Expanding Service Network - The initiative focuses on mental health welfare institutions and community settings, aiming to improve service capabilities for cognitive disorders, thereby increasing market penetration and creating significant social benefits [2]. Group 4: Strengthening Research Collaboration - The partnership with Beijing Jianguo Medical will solidify the company's collaboration network with national research institutions, with real-world data from long-term research cohorts serving as valuable assets for algorithm iteration and product optimization [2].

格隆汇1月4日丨脑动极光-B(06681.HK)宣布，公司间接全资附属公司浙江脑动极光医疗科技有限公司 ("浙江脑动极光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合作协 议》。双方将于2026年1月1日至2026年12月30日期间，围绕「认知功能评估训练精神卫生应用场景构建 与推广应用」课题开展深度合作，共同推动认知障碍数字疗法的标准化、规模化与可及化。 1.国标研究：联合研制认知障碍数字疗法核心技术指标体系、临床验证路径与应用规范，为国家标准立 项提供循证数据与草案文本。 本次合作是公司继参与国家科技重大专项及获批认知障碍数字疗法北京市重点实验室后，在认知障碍数 字疗法应用落地与生态构建方面的又一重要举措。 2.多中心试点：在杭州、南宁、武汉、牡丹江等地精神卫生福利机构及社区同步落地「脑动极光认知功 能评估与训练系统」，预计覆盖80%的目标机构，形成可复制的干预路径。 据悉，北京健国医疗依托北京健国科技集团在高端医疗科技领域的深厚产业基础和项目管理经验，专注 于康复医学技术的临床转化与推广。此次合作，正是双方将前沿数字诊疗算法与成熟产业化体系相结合 的实践，旨在共同推动认 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 簽署認知數字療法項目合作協議 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發佈的公告，目的是使廣大投資者瞭解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司浙江腦動極光醫 療科技有限公司（「浙江腦動極光」）已與北京健國醫療科技有限公司（「北京健國醫 療」）正式簽署《認知數字療法項目合作協議》（「本項目」）。雙方將於2026年1月1 日至2026年12月30日期間，圍繞「認知功能評估訓練精神衛生應用場景構建與推 廣應用」課題開展深度合作，共同推動認知障礙數字療法的標準化、規模化與可 及化（「本次合作」）。 背景介紹與本項目總體目標 合作的理由及其裨益 本次合作是 ...

Group 1 - The top three companies with the highest short-selling ratios are Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all reporting a short-selling ratio of 0.00% [1][2] - The top three companies by short-selling amount are also Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), with amounts not specified [1][2] - The companies with the highest deviation values are Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values of -0.41%, -0.41%, and -0.66% respectively [1][2] Group 2 - The top ten short-selling ratios include Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00%, with significant negative deviation values [2] - The top ten short-selling amounts also feature Cheung Kong (00001), CLP Holdings (00002), and Hong Kong and China Gas (00003), all at 0.00% short-selling ratio and notable negative deviation values [2] - The top ten companies with the highest deviation values include Energy and Energy Global (01142), Hu Shang Ayi (02589), and China Shipbuilding Defense (00317), with deviation values indicating a decline compared to their average short-selling ratios over the past 30 days [2][3]

Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

Group 1 - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase, rising over 8% to a peak of 6.82 HKD per share on December 29, with a current price of 6.73 HKD per share at 14:41 [1][4] Group 2 - On December 29, Brainstorm Cell Therapeutics announced a strategic cooperation agreement with LaHespa Health Management Holdings Group (莱贺思宝), focusing on product promotion and market expansion in Singapore [4] - This partnership marks the official launch of the company's market layout and business development in Southeast Asia, leveraging its digital therapy experience and technology accumulated in the Chinese market [4] - The collaboration is expected to enhance the company's brand influence and accelerate product implementation in local medical institutions, thereby shortening the market introduction cycle and expanding into diverse markets in digital health management [4]

Group 1 - The core viewpoint of the article highlights that Brainstorm Cell Therapeutics (06681) has seen a significant stock price increase, rising over 8% during trading and currently up 5.87% to HKD 6.67, with a trading volume of HKD 110 million [1] - The company announced a strategic cooperation agreement with Singapore's Laheyspring Health Management Group to promote product marketing and market expansion in Singapore, aiming to advance the digital health industry [1] - In terms of product promotion, the company will localize and implement its cognitive impairment digital therapy products in Singapore, providing system support and personnel training, while Laheyspring will leverage its offline stores and member resources to recommend the company's products to target users [1] Group 2 - For market expansion collaboration, both parties will integrate resources such as products, channels, brands, and technology to jointly explore the Singapore market, focusing on introducing the company's products into leading private and public hospitals in Singapore to enhance their application and popularity within the local healthcare system [1]